IL1A and COVID-19: Measuring suPAR is introducing a personalized treatment approach, because an early increase of suPAR is indicative of the excess release of damage-associated molecular patterns (DAMPs), leading to pro-inflammatory phenomena through the activation of IL-1α/β, which contributes to pathogenic inflammation in COVID-19.